Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, and Molteni Farmaceutici, a privately held specialty pharmaceutical company based in Scandicci (Florence), Italy, have entered into an exclusive collaboration framework agreement covering the commercialization of Adial Pharmaceuticals AD04 in Europe. AD04 is a small molecule serotonin-3 (5-HT3) receptor antagonist in development for the treatment of alcohol use disorder in genetically selected patients. Under the framework, Molteni receives exclusive European rights — spanning the EU and UK — to develop, manufacture, and commercialize AD04, while Adial retains rights for the United States and rest of world. The agreement is conditional on execution of a final definitive agreement.
The total potential aggregate value of the deal is estimated at nearly USD 60 million, comprising an upfront payment, milestone payments tied to development and commercial progress, and tiered royalties ranging from high single digits to low double digits on European AD04 net sales payable to Adial. Specific upfront and individual milestone amounts were not disclosed. Molteni has been granted an exclusivity period to conduct due diligence and assess requirements for European commercial launch. This represents Adial's first commercial partnership.
Deal context
AD04 is a genotype-driven 5-HT3 receptor antagonist designed to reduce alcohol consumption in patients carrying a specific single nucleotide polymorphism identified through a proprietary cheek swab-based companion diagnostic test. The drug completed a Phase 2b trial (the ONWARD study, NCT04101227), which demonstrated reductions in heavy drinking days among genetically selected patients. Adial holds US FDA Fast Track designation for AD04 in alcohol use disorder and is preparing to initiate a pivotal AD04 Phase 3 program. The company has also filed a new patent that, if granted, would extend loss of exclusivity from 2031 to 2045. AD04 is additionally under Phase 2 investigation in early Alzheimer's disease (NCT07107074).
The Molteni Farmaceutici collaboration follows a pattern consistent with Molteni's established strategy of in-licensing addiction treatment assets from US-based companies for European markets. In November 2017, Molteni signed a licensing agreement with Titan Pharmaceuticals (NASDAQ: TTNP) for exclusive European rights to Probuphine, a subdermal buprenorphine implant for opioid use disorder, in a deal worth up to USD 5.5 million in regulatory and label milestones plus commercial earn-outs. The AD04 framework, at nearly USD 60 million in potential value, represents a substantial increase in scale. For Adial, the Adial Pharmaceuticals partnership with Molteni provides access to integrated European regulatory, manufacturing, and commercial infrastructure that the company lacks as a pre-revenue entity. Adial has separately secured manufacturing agreements with Thermo Fisher Scientific and Cambrex for US clinical supply.